Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less

Clifford H. Harris, Bruce L. Dalkin, Elleen Martin, Phyllis C. Marx, Frederick R Ahmann

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Purpose: We evaluated the 3-year longitudinal changes in serial serum prostate specific antigen (PSA) levels in men with an initial PSA of 4.0 ng./ml. or less and no suspicion of prostate cancer. Materials and Methods: A total of 760 men with an initial PSA of 4.0 ng./ml. or less plus a normal or suspicious digital rectal examination and a benign prostate biopsy was enrolled into an every 4-month PSA monitoring study. Results: Of the 559 men with an initial PSA of 2.0 ng./ml. or less only 3 (0.5%) had a persistently abnormal PSA for 3 years and 1 cancer (0.2%) was detected, and 48 men had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 1 (2%) had a persistent rate of increase (2.4 ng./ml. per year) at 3 years. Of the 201 men with a PSA of 2.1 to 4.0 ng./ml. 85 had an abnormal PSA but only 37 (43%) met the criteria for biopsy. Only 8 of 23 biopsies (35%) revealed cancer. Of the 201 men 24 had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 4 had persistence for 3 years. All 4 men had cancer but they were identified as at high risk by PSA criteria. Conclusions: Men with a PSA of 2.0 ng./ml. or less are at low risk for an abnormal PSA or cancer within 3 years and annual monitoring may not be necessary. However, annual monitoring is clinically useful in men with an initial PSA of 2.1 to 4.0 ng./ml. Also, serial monitoring with interval testing in men whose PSA becomes greater than 4.0 ng./ml. is beneficial in identifying a high risk group requiring biopsy. Finally, PSA velocity did not add further to cancer detection in this population.

Original languageEnglish (US)
Pages (from-to)1740-1743
Number of pages4
JournalJournal of Urology
Volume157
Issue number5
DOIs
StatePublished - May 1997

Fingerprint

Prostate-Specific Antigen
Biopsy
Neoplasms
Digital Rectal Examination
Prostate
Prostatic Neoplasms

Keywords

  • prostate
  • prostate-specific antigen
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less. / Harris, Clifford H.; Dalkin, Bruce L.; Martin, Elleen; Marx, Phyllis C.; Ahmann, Frederick R.

In: Journal of Urology, Vol. 157, No. 5, 05.1997, p. 1740-1743.

Research output: Contribution to journalArticle

Harris, Clifford H. ; Dalkin, Bruce L. ; Martin, Elleen ; Marx, Phyllis C. ; Ahmann, Frederick R. / Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less. In: Journal of Urology. 1997 ; Vol. 157, No. 5. pp. 1740-1743.
@article{cdd975b18b8b4194a91f538faeb913e5,
title = "Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less",
abstract = "Purpose: We evaluated the 3-year longitudinal changes in serial serum prostate specific antigen (PSA) levels in men with an initial PSA of 4.0 ng./ml. or less and no suspicion of prostate cancer. Materials and Methods: A total of 760 men with an initial PSA of 4.0 ng./ml. or less plus a normal or suspicious digital rectal examination and a benign prostate biopsy was enrolled into an every 4-month PSA monitoring study. Results: Of the 559 men with an initial PSA of 2.0 ng./ml. or less only 3 (0.5{\%}) had a persistently abnormal PSA for 3 years and 1 cancer (0.2{\%}) was detected, and 48 men had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 1 (2{\%}) had a persistent rate of increase (2.4 ng./ml. per year) at 3 years. Of the 201 men with a PSA of 2.1 to 4.0 ng./ml. 85 had an abnormal PSA but only 37 (43{\%}) met the criteria for biopsy. Only 8 of 23 biopsies (35{\%}) revealed cancer. Of the 201 men 24 had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 4 had persistence for 3 years. All 4 men had cancer but they were identified as at high risk by PSA criteria. Conclusions: Men with a PSA of 2.0 ng./ml. or less are at low risk for an abnormal PSA or cancer within 3 years and annual monitoring may not be necessary. However, annual monitoring is clinically useful in men with an initial PSA of 2.1 to 4.0 ng./ml. Also, serial monitoring with interval testing in men whose PSA becomes greater than 4.0 ng./ml. is beneficial in identifying a high risk group requiring biopsy. Finally, PSA velocity did not add further to cancer detection in this population.",
keywords = "prostate, prostate-specific antigen, prostatic neoplasms",
author = "Harris, {Clifford H.} and Dalkin, {Bruce L.} and Elleen Martin and Marx, {Phyllis C.} and Ahmann, {Frederick R}",
year = "1997",
month = "5",
doi = "10.1016/S0022-5347(01)64848-1",
language = "English (US)",
volume = "157",
pages = "1740--1743",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less

AU - Harris, Clifford H.

AU - Dalkin, Bruce L.

AU - Martin, Elleen

AU - Marx, Phyllis C.

AU - Ahmann, Frederick R

PY - 1997/5

Y1 - 1997/5

N2 - Purpose: We evaluated the 3-year longitudinal changes in serial serum prostate specific antigen (PSA) levels in men with an initial PSA of 4.0 ng./ml. or less and no suspicion of prostate cancer. Materials and Methods: A total of 760 men with an initial PSA of 4.0 ng./ml. or less plus a normal or suspicious digital rectal examination and a benign prostate biopsy was enrolled into an every 4-month PSA monitoring study. Results: Of the 559 men with an initial PSA of 2.0 ng./ml. or less only 3 (0.5%) had a persistently abnormal PSA for 3 years and 1 cancer (0.2%) was detected, and 48 men had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 1 (2%) had a persistent rate of increase (2.4 ng./ml. per year) at 3 years. Of the 201 men with a PSA of 2.1 to 4.0 ng./ml. 85 had an abnormal PSA but only 37 (43%) met the criteria for biopsy. Only 8 of 23 biopsies (35%) revealed cancer. Of the 201 men 24 had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 4 had persistence for 3 years. All 4 men had cancer but they were identified as at high risk by PSA criteria. Conclusions: Men with a PSA of 2.0 ng./ml. or less are at low risk for an abnormal PSA or cancer within 3 years and annual monitoring may not be necessary. However, annual monitoring is clinically useful in men with an initial PSA of 2.1 to 4.0 ng./ml. Also, serial monitoring with interval testing in men whose PSA becomes greater than 4.0 ng./ml. is beneficial in identifying a high risk group requiring biopsy. Finally, PSA velocity did not add further to cancer detection in this population.

AB - Purpose: We evaluated the 3-year longitudinal changes in serial serum prostate specific antigen (PSA) levels in men with an initial PSA of 4.0 ng./ml. or less and no suspicion of prostate cancer. Materials and Methods: A total of 760 men with an initial PSA of 4.0 ng./ml. or less plus a normal or suspicious digital rectal examination and a benign prostate biopsy was enrolled into an every 4-month PSA monitoring study. Results: Of the 559 men with an initial PSA of 2.0 ng./ml. or less only 3 (0.5%) had a persistently abnormal PSA for 3 years and 1 cancer (0.2%) was detected, and 48 men had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 1 (2%) had a persistent rate of increase (2.4 ng./ml. per year) at 3 years. Of the 201 men with a PSA of 2.1 to 4.0 ng./ml. 85 had an abnormal PSA but only 37 (43%) met the criteria for biopsy. Only 8 of 23 biopsies (35%) revealed cancer. Of the 201 men 24 had a PSA velocity of 0.8 ng./ml. per year or more at year 1 but only 4 had persistence for 3 years. All 4 men had cancer but they were identified as at high risk by PSA criteria. Conclusions: Men with a PSA of 2.0 ng./ml. or less are at low risk for an abnormal PSA or cancer within 3 years and annual monitoring may not be necessary. However, annual monitoring is clinically useful in men with an initial PSA of 2.1 to 4.0 ng./ml. Also, serial monitoring with interval testing in men whose PSA becomes greater than 4.0 ng./ml. is beneficial in identifying a high risk group requiring biopsy. Finally, PSA velocity did not add further to cancer detection in this population.

KW - prostate

KW - prostate-specific antigen

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0030986966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030986966&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)64848-1

DO - 10.1016/S0022-5347(01)64848-1

M3 - Article

C2 - 9112517

AN - SCOPUS:0030986966

VL - 157

SP - 1740

EP - 1743

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -